ADVOCATE. CONNECT. INNOVATE.

CLSA Wire

Policy Updates
Nov
04
CLSA in the San Diego Union-Tribune: Drug pricing bill will stop innovative new medicines, California trade groups say

California Life Sciences Association was recently featured in the San Diego Union-Tribune regarding its new study on the impact of international reference pricing. Up to 88 percent fewer new drug approvals projected in study commissioned by Biocom and California Life Sciences Association.
Category: CLSA HomeCLSA WireIn the NewsWashington
Oct
29
44 Life Sciences Organizations Across the Country Agree: Foreign Price Controls Would Crush Life-Saving Biomedical Innovation for Patients

Life Sciences Trade Groups Warn Congress: International Reference Pricing Proposals Included in Bills like H.R. 3 Undermine Hope for Patients and America’s Leadership in Biomedical Innovation
Category: CLSA HomeCLSA WirePress ReleasesWashington
Oct
28
44 Life Sciences Organizations Across the Country Agree: Foreign Price Controls Would Crush Life-Saving Biomedical Innovation for Patients

Life Sciences Trade Groups Warn Congress: International Reference Pricing Proposals Included in Bills like H.R. 3 Undermine Hope for Patients and America’s Leadership in Biomedical Innovation
Category: CLSA WireWashington
Oct
28
2019 State Legislative Year in Review

While the 2018 legislative year marked arguably the most successful year ever for CLSA in Sacramento and provided a number of major policy issues on which to focus our energy, the 2019 legislative year was “death by a thousand cuts,” requiring CLSA to spread its attention broadly across a host of issues outside of our traditional areas of focus.

Category: CLSA HomeCLSA WireSacramento
Oct
25
CLSA Leads Multi-State Organization Letter to Congressional Leadership Opposing International Reference Pricing

CLSA organized a multi-state life sciences association letter to House and Senate Leadership, expressing our strong concerns with recent legislative proposals that threaten to undermine America’s global leadership in biomedical innovation by introducing international reference pricing or foreign price controls.

Category: CLSA HomeCLSA WireWashington
Oct
24
CLSA Helps Educate Members of State Legislature with Life Sciences Company Tours at Allergan and Edwards Lifesciences

On Oct. 22, CLSA, in partnership with Allergan and Edwards Lifesciences, hosted facility tour and roundtable discussion with the nearly 40 personnel, including state legislators, legislative staff, the Orange County Medical Association, and other key stakeholders to educate policymakers and stakeholders on the value of life sciences innovation in Orange County.
Category: CLSA HomeCLSA WireSacramento
Oct
21
CLSA and Covington & Burling Host Member Roundtable with FDA’s Director of the Office of New Drugs (OND) in San Francisco

On Oct 17, CLSA and Covington & Burling, LLP hosted Keith Flanagan, Director, and Maarika Kimbrell, Deputy Director, of FDA’s Office of New Drugs (OND) for a roundtable discussion on drug development.

Category: CLSA HomeCLSA WireWashington
Oct
15
CLSA Op-Ed in CALMatters: California leads the way in precision medicine

Precision medicine uses some of the world’s most sophisticated technologies to find the root causes of each patient’s unique condition and apply the best, most precise treatments. California is a biomedical juggernaut, and the precision medicine research being funded today will impact patients around the world. Learn how California is leading the way in precision medicine research.
Category: CLSA HomeCLSA WireIn the NewsOp EdSacramento
Sep
23
Many Business-Supported Changes to California’s Privacy and Data Security Law Fail to Reach the Governor

With the impending January 1, 2020 effective date of the California Consumer Privacy Act (CCPA), the Legislature considered multiple bills this year that sought to clarify the law’s requirements and facilitate businesses’ compliance.
Category: CLSA WireSacramento
Sep
23
CLSA Opposes New Dangerous Price Controls Proposal Threatening California’s Biopharmaceutical Innovation Ecosystem

On Sept. 19, House Speaker Nancy Pelosi (D-San Francisco) unveiled legislation in the form of the Lower Drug Costs Now Act (H.R. 3), an unprecedented sweeping proposal that would transfer most domestic drug pricing decision-making to U.S. and European government bureaucrats, and eviscerate the free market model that has promoted innovation, cures and treatments for millions of patients.
Category: CLSA HomeCLSA WireWashington
MENU